Literature DB >> 16435174

Social outcome in treated individuals with inherited metabolic disorders: UK study.

M Bhat1, C Haase, P J Lee.   

Abstract

Few data exist on the long-term social outcome of patients with inherited metabolic disorders, despite the fact that increasing numbers are surviving into adulthood. Here we report the findings of 329 patients aged from 11 to 70 years, of whom 172 had phenylketonuria, 38 had homocystinuria and 33 had galactosaemia. Twenty-eight per cent had no formal education qualifications, 59% were employed, but only 17% were in professional jobs (social classes I and II). The time of diagnosis and treatment had a significant impact on outcome in phenylketonuria, as did pyridoxine responsiveness or lack of it in homocystinuria. Effects on outcome in galactosaemia were not clear. Social integration is an important outcome of treatment of chronic disorders in childhood and warrants further study in this growing patient population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16435174     DOI: 10.1007/s10545-005-0159-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.750


  12 in total

1.  Long-term prognosis in galactosaemia: results of a survey of 350 cases.

Authors:  D D Waggoner; N R Buist; G N Donnell
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

2.  The intellectual abilities of early-treated individuals with pyridoxine-nonresponsive homocystinuria due to cystathionine beta-synthase deficiency.

Authors:  S Yap; H Rushe; P M Howard; E R Naughten
Journal:  J Inherit Metab Dis       Date:  2001-08       Impact factor: 4.982

3.  The relationship of genotype to cognitive outcome in galactosaemia.

Authors:  J P Shield; E J Wadsworth; A MacDonald; A Stephenson; L Tyfield; J B Holton; N Marlow
Journal:  Arch Dis Child       Date:  2000-09       Impact factor: 3.791

4.  The molecular basis of cystathionine beta-synthase deficiency in Australian patients: genotype-phenotype correlations and response to treatment.

Authors:  Mette Gaustadnes; Bridget Wilcken; Jana Oliveriusova; Jim McGill; Janice Fletcher; Jan P Kraus; David E Wilcken
Journal:  Hum Mutat       Date:  2002-08       Impact factor: 4.878

5.  Intelligence and professional career in young adults treated early for phenylketonuria.

Authors:  H Schmidt; P Burgard; J Pietz; A Rupp
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

6.  Care of the adult with phenylketonuria.

Authors:  R Koch; C Azen; E G Friedman; K Fishler; C Baumann-Frischling; T Lin
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

7.  Long-term outcome in 134 patients with galactosaemia.

Authors:  S Schweitzer; Y Shin; C Jakobs; J Brodehl
Journal:  Eur J Pediatr       Date:  1993-01       Impact factor: 3.183

8.  Galactosemia: how does long-term treatment change the outcome?

Authors:  R Gitzelmann; B Steinmann
Journal:  Enzyme       Date:  1984

Review 9.  Early diagnosis of inherited metabolic disorders towards improving outcome: the controversial issue of galactosaemia.

Authors:  Susanne Schweitzer-Krantz
Journal:  Eur J Pediatr       Date:  2003-11-12       Impact factor: 3.183

10.  Successful adjustment to society by adults with phenylketonuria.

Authors:  R Koch; M Yusin; K Fishler
Journal:  J Inherit Metab Dis       Date:  1985       Impact factor: 4.982

View more
  7 in total

1.  The neuropsychological profile of galactosaemia.

Authors:  Claire M Doyle; Shelley Channon; Danuta Orlowska; Philip J Lee
Journal:  J Inherit Metab Dis       Date:  2010-07-06       Impact factor: 4.982

2.  The male reproductive system in classic galactosemia: cryptorchidism and low semen volume.

Authors:  Cynthia S Gubbels; Corrine K Welt; John C M Dumoulin; Simon G F Robben; Catherine M Gordon; Gerard A J Dunselman; M Estela Rubio-Gozalbo; Gerard T Berry
Journal:  J Inherit Metab Dis       Date:  2012-10-11       Impact factor: 4.982

3.  Diversity of approaches to classic galactosemia around the world: a comparison of diagnosis, intervention, and outcomes.

Authors:  Patricia P Jumbo-Lucioni; Kathryn Garber; John Kiel; Ivo Baric; Gerard T Berry; Annet Bosch; Alberto Burlina; Ana Chiesa; Maria Luz Couce Pico; Sylvia C Estrada; Howard Henderson; Nancy Leslie; Nicola Longo; Andrew A M Morris; Carlett Ramirez-Farias; Susanne Schweitzer-Krantz; Susanne Scheweitzer-Krantz; Catherine Lynn T Silao; Marcela Vela-Amieva; Susan Waisbren; Judith L Fridovich-Keil
Journal:  J Inherit Metab Dis       Date:  2012-03-27       Impact factor: 4.982

4.  Pregnancy issues in inherited metabolic disorders.

Authors:  Philip J Lee
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

Review 5.  Guidelines for the diagnosis and management of cystathionine beta-synthase deficiency.

Authors:  Andrew A M Morris; Viktor Kožich; Saikat Santra; Generoso Andria; Tawfeg I M Ben-Omran; Anupam B Chakrapani; Ellen Crushell; Mick J Henderson; Michel Hochuli; Martina Huemer; Miriam C H Janssen; Francois Maillot; Philip D Mayne; Jenny McNulty; Tara M Morrison; Helene Ogier; Siobhan O'Sullivan; Markéta Pavlíková; Isabel Tavares de Almeida; Allyson Terry; Sufin Yap; Henk J Blom; Kimberly A Chapman
Journal:  J Inherit Metab Dis       Date:  2016-10-24       Impact factor: 4.982

Review 6.  Sweet and sour: an update on classic galactosemia.

Authors:  Ana I Coelho; M Estela Rubio-Gozalbo; João B Vicente; Isabel Rivera
Journal:  J Inherit Metab Dis       Date:  2017-03-09       Impact factor: 4.982

7.  Evaluation of quality of life and description of the sociodemographic state in adolescent and young adult patients with phenylketonuria (PKU).

Authors:  Eva Simon; Martin Schwarz; Judith Roos; Nico Dragano; Max Geraedts; Johannes Siegrist; Gudrun Kamp; Udo Wendel
Journal:  Health Qual Life Outcomes       Date:  2008-03-26       Impact factor: 3.186

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.